Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2012 1
2013 1
2014 2
2015 2
2016 3
2017 3
2018 3
2019 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L. Sistigu A, et al. Among authors: fend l. Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26. Nat Med. 2014. PMID: 25344738 Clinical Trial.
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Pol JG, et al. Among authors: fend l. Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Oncoimmunology. 2018. PMID: 30524901 Free PMC article. Review.
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment.
Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N, Foloppe J, Fend L, Spring-Giusti C, Quéméneur E, Marchand JB. Azar F, et al. Among authors: fend l. J Immunother Cancer. 2024 Jul 25;12(7):e009302. doi: 10.1136/jitc-2024-009302. J Immunother Cancer. 2024. PMID: 39060022 Free PMC article.
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Semmrich M, Marchand JB, Fend L, Rehn M, Remy C, Holmkvist P, Silvestre N, Svensson C, Kleinpeter P, Deforges J, Junghus F, Cleary KL, Bodén M, Mårtensson L, Foloppe J, Teige I, Quéméneur E, Frendéus B. Semmrich M, et al. Among authors: fend l. J Immunother Cancer. 2022 Jan;10(1):e003488. doi: 10.1136/jitc-2021-003488. J Immunother Cancer. 2022. PMID: 35058324 Free PMC article.
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.
Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L. Ivagnès A, et al. Among authors: fend l. Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018. Oncoimmunology. 2017. PMID: 30524877 Free PMC article.
Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus.
Remy C, Pintado E, Dunlop M, Schön S, Kleinpeter P, Rozanes H, Fend L, Brandely R, Geist M, Suhner D, Winter E, Silvestre N, Huguet C, Fitzgerald P, Quéméneur E, Marchand JB. Remy C, et al. Among authors: fend l. Front Bioeng Biotechnol. 2023 Nov 15;11:1247802. doi: 10.3389/fbioe.2023.1247802. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 38053848 Free PMC article.
Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient.
Hinterleitner C, Steurer M, Dörfel D, Heitmann J, Kreisselmeier KP, Müller K, Kopp HG, Wirths S, Haap M, de Fend LQ, Horger M, Rodriguez-Galindo C, Kanz L, Müller MR. Hinterleitner C, et al. Among authors: de fend lq. Ann Hematol. 2019 Jan;98(1):227-230. doi: 10.1007/s00277-018-3421-7. Epub 2018 Jul 6. Ann Hematol. 2019. PMID: 29980874 No abstract available.
Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.
Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L. Fend L, et al. Oncoimmunology. 2016 May 13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017. Oncoimmunology. 2016. PMID: 28197362 Free PMC article.
17 results